Profile of farletuzumab and its potential in the treatment of solid tumors
about
The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.Advances in ovarian cancer therapy.In Vitro and In Vivo evaluation of a novel folate-targeted theranostic nanoemulsion of docetaxel for imaging and improved anticancer activity against ovarian cancers.
P2860
Profile of farletuzumab and its potential in the treatment of solid tumors
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Profile of farletuzumab and its potential in the treatment of solid tumors
@ast
Profile of farletuzumab and its potential in the treatment of solid tumors
@en
Profile of farletuzumab and its potential in the treatment of solid tumors
@nl
type
label
Profile of farletuzumab and its potential in the treatment of solid tumors
@ast
Profile of farletuzumab and its potential in the treatment of solid tumors
@en
Profile of farletuzumab and its potential in the treatment of solid tumors
@nl
prefLabel
Profile of farletuzumab and its potential in the treatment of solid tumors
@ast
Profile of farletuzumab and its potential in the treatment of solid tumors
@en
Profile of farletuzumab and its potential in the treatment of solid tumors
@nl
P2860
P356
P1476
Profile of farletuzumab and its potential in the treatment of solid tumors
@en
P2093
Hiroaki Itamochi
Seiya Sato
P2860
P304
P356
10.2147/OTT.S98242
P407
P577
2016-01-01T00:00:00Z